Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

al compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; plans and timing for commercialization of Qutenza; and development activities for NGX-1998 and other product candidates, including regulatory submissions and any outcomes of such submissions. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; inability or delay in establishing sales infrastructure to support potential commercialization; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; physician or patient reluctance to use Qutenza or NGX-1998, if approved; other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates; and our ability to raise additional capital as needed. For further information regarding these and other risks r
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... -- Research and Markets  has announced ... Report 2014" report to their offering. ... Palmitic Acid Industry Report 2014 is a professional and ... palmitic acid industry. The report provides a ... and industry chain structure. The palmitic acid market analysis ...
(Date:11/26/2014)... 21, 2014 (PRWEB) November 26, 2014 ... communications network, today announced the organization has won a ... Club Awards. Digitas Health LifeBrands was honored with a ... other PHCG agencies received eight Awards of Excellence. ... aspects of pharmaceutical advertising and promotion. The Awards provide ...
(Date:11/26/2014)... The announced sales of three healthcare units ... to expand in non-healthcare areas, says Kalorama Information. Siemens ... firm says that  Siemens is the third largest company ... the IVD market , with 5.5 billion in IVD ... would likely affect IVD market shares.  ...
(Date:11/26/2014)... PMG Research, Inc. announced today the ... network of sites that provide clinical research services to pharmaceutical ... lives through its partnerships with large physician practices and integrated ... locations in the Southeastern United States and spans over 60 ... board will be held by: Dr. Robert Holmes, MD, ...
Breaking Biology Technology:Global Palmitic Acid Industry Report 2014 2Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3
... ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... 27 PDL BioPharma, Inc. (PDL, ... it has entered into separate privately negotiated exchange agreements under ... the Company,s outstanding 2.00% Convertible Senior Notes due February 15, ... holders of the 2012 Notes will receive $92.0 million in ...
Cached Biology Technology:Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 2Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 3Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 4Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 5Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 6Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 7Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 8The New deCODE Map of the Human Genome 2The New deCODE Map of the Human Genome 3The New deCODE Map of the Human Genome 4The New deCODE Map of the Human Genome 5The New deCODE Map of the Human Genome 6The New deCODE Map of the Human Genome 7The New deCODE Map of the Human Genome 8The New deCODE Map of the Human Genome 9PDL BioPharma Announces Exchange to Retire 2.00% Convertible Senior Notes Due February 15, 2012 2PDL BioPharma Announces Exchange to Retire 2.00% Convertible Senior Notes Due February 15, 2012 3
(Date:11/21/2014)... Calif. , Nov. 20, 2014   Atmel® ... leader in microcontroller (MCU) and touch technology solutions, today ... temperature sensors with the widest V cc ... higher temperature accuracy and faster I 2 C bus ... and serial EEPROM memory making them ideal for consumer, ...
(Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
(Date:11/7/2014)... 2014  In conjunction with the Glendale ... Community Foundation of the Verdugos has announced the " ... a $250,000 initiative to keep the Verdugo Regional Crime Lab ... six months of existence, the Lab has processed more than ... law enforcement. "Because our number one priority is ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... With only two weeks to go and almost a ... 2013 have reached their final stages. This year,s conference ... Simons will deliver the opening keynote lecture and explain ... cells work. In further keynote lectures, Hans Clevers will ...
... 9, 2013 Cytos Biotechnology Ltd (SIX:CYTN) today ... CYT003, a first-in-class immune modulator in clinical development as a ... data published in the March issue of The Journal ... at the European Respiratory Society Annual Congress in ...
... 2013 Disease-causing bacteria stink literally and the ... the basis for a faster and simpler new way to ... here today at the 246th National Meeting & Exposition of ... The new test produces results in 24 hours, compared ...
Cached Biology News:All set for The EMBO Meeting 2013 2Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 2Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 3Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 4Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 5New 'artificial nose' device can speed diagnosis of sepsis 2
EML1 (K-16)...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
Bovine Pulmonary Artery Endothelial Cells (BPAEC) (>500,000 cells)...
Biology Products: